Cancer cachexia– Pipeline Review, 2019

Cachexia is the loss of fat and muscle due to a chronic disease, such as cancer, chronic renal failure, HIV and others. Cachexia causes loss of appetite, weight loss, fatigue and weakness. Cancer cachexia or cancer-induced cachexia is associated with presence of tumors. It affects an estimated 60% of the 1.6 million cancer patients in the U.S., alone. The prevalence of cachexia in cancer patients is an estimated 80% among late-stage cancer patients, and cancer-induced cachexia is responsible for around 20% deaths among cancer patients globally. The prevalence of cancer-induced cachexia differs depending upon the location of the cancer, ranging from 60% in lung cancer patients, to more than 80% among pancreatic and colorectal cancer patients.

There is no adequate treatment to treat cancer cachexia. Some of the commonly referred treatments are adequate diet, intake of nutrition supplement, exercise, medications. The medications include, Megace (megestrol), Thalidomide, Zyloprim (allopurinol), Celebrex (celecoxib), L-Carnitine and many others.

Pharmaceutical companies and research institutes have focussed on studying and developing new methods for the treatment of cancer cachexia. For instance; OHR/AVR118, which is being studied by Ohr Pharmaceutical Inc., is currently in phase-2 clinical trials for open label study with OHR/AVR118 in advanced cancer patients with Anorexia-Cachexia.

At present more than 60% of the pipeline candidates for cancer cachexia are in phase 2 and phase 3 stages combined. Majority of the studies have been sponsored by pharmaceutical companies.

Report Description

The report on ‘Cancer cachexia– Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for allergic conjunctivitis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for cancer cachexia.

The report on ‘Cancer cachexia– Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for cancer cachexia


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for cancer cachexia


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary